This randomized double-blind safety study tested 750 or 1,500 mg/day NMN against placebo for four weeks in 30 healthy adults.
The study was designed as an overdose-intake safety assessment rather than an efficacy trial. Its main contribution is short-term tolerability information at doses higher than those used in many earlier NMN studies.
The small sample and four-week duration mean it cannot establish uncommon adverse-event risks or long-term safety.
Key findings
The trial directly evaluated 750 and 1,500 mg/day oral NMN for four weeks.
The publication reported short-term safety and laboratory monitoring across the high-dose groups.
The study was designed for safety, not clinical efficacy.
Commercial Teijin/NOMON affiliations were present among four of five authors.
What it cannot establish
Only 30 participants.
Only four weeks of exposure.
Not powered to detect rare adverse events.
Healthy-adult findings may not generalize to people with significant chronic disease.
HealthspanX claim boundary: This study informs short-term tolerability of high-dose NMN in healthy adults. It does not establish long-term safety, clinical benefit, anti-aging efficacy or product equivalence.
